MindRank Pharma Showcases AI-Driven Molecular Glue Platform at TPD2024 Forum Amid IPO Filing

On October 22-23, 2024, the TPD2024 Targeted Protein Degradation Drug Development Forum was successfully held in Shanghai.Dr. Long Zhang, Co-founder of MindRankInvited to attend and deliver a keynote speech, sharing the company's self-developedHow Does AI Drug Discovery Platform Molecule Pro™ EmpowerDifferentiated and Batch Development of Molecular Glue Projects.

MindRank Co-Founder Zhang Long Delivers Keynote Speech

Molecular glue provides a groundbreaking strategy for traditional small molecule drug development, capable of targeting protein targets previously considered undruggable. AI technology has also brought new momentum to the breakthroughs in molecular glue. The Molecule Pro™ platform, independently developed and upgraded by the MindRank team,InnovationNewly integrated full-scale molecular glue/PROTAC biological and chemical data, combined with large model and manual verification, to empower the rational design and rapid development of a new generation of molecular glue drugs with AI.

Using the leading AI pharmaceutical platform Molecule Pro™, "MindRank"MindRank's self-developed molecular glue drug MRANK-103 is proceeding smoothly through the IND-Enabling stage of research.The project targets the MYC signaling pathway and focuses on eukaryotic translation and transcription regulatory factors. The obtained PCC candidate molecules have demonstrated potent anti-tumor cell proliferation activity in multiple tumor models, with favorable pharmacokinetics and safety.

Currently, MindRank has laid out a series of molecular glue drug pipelines based on the Molecule Pro™ platform technology, while continuously innovating and iterating molecular glue and PROTAC drug development technologies, aiming to provide better treatment options for patients.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby helping more lives regain health.

MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution, Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's most socially impactful startups."

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai